Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis.

Yun, Nicole K; Alrifai, Taha; Miller, Ira J; Shammo, Jamile M

Yun, Nicole K; Alrifai, Taha; Miller, Ira J; Shammo, Jamile M.

Afiliación

Yun NK; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Alrifai T; Division of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.
Miller IJ; Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA.
Shammo JM; Division of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.

Case Rep Oncol ; 15(1): 126-132, 2022.

Article en En | MEDLINE | ID: mdl-35350804

Palabras clave

Fedratinib; Heavily pretreated; Luspatercept; Myeloproliferative neoplasm; Primary myelofibrosis; Transfusion independence

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Case Rep Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google